Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1Breast 1

Conditions

Ovarian Neoplasms 4Colorectal Neoplasms, Hereditary Nonpolyposis 3Breast Neoplasms 3Prostatic Neoplasms 2Hereditary Breast and Ovarian Cancer Syndrome 2Endometrial Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Syndromes, Hereditary 1Melanoma 1Kidney Neoplasms 1Fanconi Anemia, Complementation Group D1 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

olaparib 5talazoparib 1liposomal doxorubicin 1Trabectedin 1Surveys and Questionnaires 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Genetic Counseling × Gynecologic × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡